{"schema_version":"secwatch.filing_event.v1","accession":"0001090872-24-000036","form_type":"8-K","ticker":"A","cik":"0001090872","company_name":"AGILENT TECHNOLOGIES, INC.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.146046+00:00","generated_at":"2026-05-31T06:33:52.414983+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"medium","headline":"Agilent recasts segment financials moving cell analysis to diagnostics and genomics","bullets":["Move of cell analysis from life sciences/applied markets to diagnostics/genomics segment effective Q1 FY2024.","Historical FY2023 data recast in Exhibit 99.1; three reportable segments unchanged.","No change to Agilent CrossLab segment; recast for comparability only."],"urls":{"canonical":"https://secwatch.observer/filing/0001090872-24-000036","json":"https://secwatch.observer/filing/0001090872-24-000036.json","markdown":"https://secwatch.observer/filing/0001090872-24-000036.md","text":"https://secwatch.observer/filing/0001090872-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1090872/000109087224000036/0001090872-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1090872/000109087224000036/a-20240903_d2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:33:52.414983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}